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Abstract
The HIV-specific cytotoxic T lymphocyte (CTL) response is a critical component in controlling viral replication in vivo, but
ultimately fails in its ability to eradicate the virus. Our intent in these studies is to develop ways to enhance and restore the
HIV-specific CTL response to allow long-term viral suppression or viral clearance. In our approach, we sought to genetically
manipulate human hematopoietic stem cells (HSCs) such that they differentiate into mature CTL that will kill HIV infected
cells. To perform this, we molecularly cloned an HIV-specific T cell receptor (TCR) from CD8+ T cells that specifically targets
an epitope of the HIV-1 Gag protein. This TCR was then used to genetically transduce HSCs. These HSCs were then
introduced into a humanized mouse containing human fetal liver, fetal thymus, and hematopoietic progenitor cells, and
were allowed to differentiate into mature human CD8+ CTL. We found human, HIV-specific CTL in multiple tissues in the
mouse. Thus, genetic modification of human HSCs with a cloned TCR allows proper differentiation of the cells to occur in
vivo, and these cells migrate to multiple anatomic sites, mimicking what is seen in humans. To determine if the presence of
the transgenic, HIV-specific TCR has an effect on suppressing HIV replication, we infected with HIV-1 mice expressing the
transgenic HIV-specific TCR and, separately, mice expressing a non-specific control TCR. We observed significant
suppression of HIV replication in multiple organs in the mice expressing the HIV-specific TCR as compared to control,
indicating that the presence of genetically modified HIV-specific CTL can form a functional antiviral response in vivo. These
results strongly suggest that stem cell based gene therapy may be a feasible approach in the treatment of chronic viral
infections and provide a foundation towards the development of this type of strategy.
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Introduction
Human hematopoietic stem cells (HSCs), through development
in the thymus, are capable of producing progeny T cells that
generally display one of a vast repertoire of T cell receptors
(TCRs). In the case of many non-persistent viral infections, T cells
bearing TCRs specific to viral antigens mediate a potent antiviral
response that results in the clearance of the virus from the body.
Even in the presence of most persistent viral infections, a potent T
cell response is mounted; however it often fails to clear the virus
from the body. A critical component of the T cell antiviral
response is the CD8+ cytotoxic T lymphocyte (CTL), whose
primary function is to recognize viral antigens (in the context of
human leukocyte antigen class I (HLA I)) and kill virus-infected
cells. In HIV infection, the potent antiviral CTL response is
critical for establishing relative control of viral replication during
the acute and chronic infection stages of the disease [1–6].
However, unlike what is observed in most non-persistent viral
infections, the CTL response fails to clear HIV from the body. The
magnitude, breadth, functional quality, and kinetics of the
antiviral CTL response all are critical in controlling ongoing viral
replication; however, the reasons for the failure to rid the body of
virus are not completely understood [7,8]. Ongoing viral
replication and viral evolution in the infected host is one
important, although highly confounding, factor in the persistence
of HIV in chronic infection [4,5]. Even under effective
antiretroviral therapy (ART), the virus is not cleared from the
body and the level of HIV specific CTLs declines, likely due to
lower levels of antigen to stimulate the persistence/generation of
these cells [9,10]. Due to the importance of T cell responses in
controlling and eliminating viral infection there exists a great need
to explore ways to enhance antiviral T cell immune responses.
Recently, much of attention in HIV research has focused on
ways to enhance or correct the defects in HIV-specific CTL
responses. Gene therapy-based approaches that augment immu-
nity towards viral antigens represent unique, yet largely unex-
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previously examined the feasibility of a stem cell-based gene
therapy approach to enhance cell-mediated immunity towards
chronic HIV infection. In these studies, we demonstrated that
human HSCs genetically modified with genes encoding a human
HIV-specific TCR can produce mature, fully functional T cells in
human thymus implants in severe combined immunodeficient
(SCID) mice. The resulting genetically directed CD8+ T cells are
capable of killing HIV antigen-expressing cells ex vivo [11].
Further, we showed that the appropriate restricting human
leukocyte antigen (HLA) class I molecule is required for proper
development of transgenic TCR-containing CTLs. In all, our
earlier studies demonstrated that TCR-modified human HSCs can
be directed to develop into mature CTLs in a human thymus
environment in the context of the proper HLA type. However, as
the SCID-hu mouse model demonstrated poor peripheral
reconstitution and function of human immune cells, these studies
did not address the ability of these cells to suppress HIV
replication in vivo.
In the present studies, we examined the ability of genetically
modified T cells derived from HSC transduced with a single HIV-
specific TCR to suppress viral replication in vivo. We utilized a
modified version of a newly established humanized mouse model,
the non-obese diabetic (NOD)-SCID, common gamma chain
knockout (cc2/2), humanized bone marrow, fetal liver and
thymus (the NSG-BLT) mouse model, which allows the generation
of peripheral human immune responses, and serves as an effective
model for HIV infection and pathogenesis [12–14] (see Figure 1A).
These humanized mice display multilineage human hematopoiesis
and systemic engraftment of peripheral organs with human blood
cell types including T lineage cells, B lineage cells, myeloid lineage
cells, NK cells, as well as cells from other lineages [12] (and see
Figure 1B). We modified human hematopoietic stem cells in this
model with molecularly cloned genes corresponding to a TCR
specific to the HIV-1 Gag 77–85 SLYNTVATL (SL9) epitope to
allow the production of mature HIV-specific CTLs in multiple
organs of these reconstituted mice. We determined that human T
cells that expressed the HIV-specific TCR were capable of
suppressing HIV replication in vivo and preventing or slowing viral
damage to the engrafted human immune system. These studies
establish a system to examine ‘‘genetic vaccination’’ approaches
that target chronic viral infection and to more closely examine
mechanisms of human antiviral immunity in vivo.
Results
Genetic modification and multilineage human
hematopoiesis in vivo
We have previously demonstrated that human hematopoietic
stem cells can be genetically modified by delivering a gene for an
HIV-specific TCR, and develop into mature T cells in an HLA-
restricted fashion in the human thymus of SCID-hu mice [11].
These newly produced, SL9 gag antigen-specific, naive T cells
were determined to be capable of producing IFN-c in response to
peptide stimulation and were found to be lytic to SL9 peptide
loaded target cells. However, it was not known whether these
genetically modified HIV-specific CTLs could traffic to relevant
organs in the mice and whether they were capable of killing HIV
infected cells in vivo. To address this question, we established an
improved model, based on the NSG-BLT model previously shown
to allow HIV replication [15,16], as a surrogate system to assess
the antiviral efficacy of engineered, HIV-specific T cells in vivo.
NSG mice were implanted with human fetal liver-derived CD34+
HSCs that had been modified with a lentiviral vector containing
the genes for a TCR targeting the HIV Gag SL9 epitope, or as a
control, with HSCs modified with a lentiviral vector containing a
non-HIV-specific TCR with unknown specificity. In addition,
these mice received implantation of human fetal Thymus and
Liver under the kidney capsule to facilitate human T cell
development. Hence, we term this the NSG-CTL model
(Figure 1A).
As genetic manipulation of HSCs is required in this model, we
initially determined the effects on this type of lentiviral
transduction on multilineage hematopoietic potential of HSCs in
the humanized mice. Phenotypic markers of human hematopoiesis
were examined by flow cytometry in mice within 6 weeks following
implantation of human tissues. One hundred percent of the mice
receiving human tissue had human cells in the peripheral blood,
including myeloid, natural killer (NK), T cell, and B cell lineages
(Figure 1B). In these mice, the average percentage of human
CD45+ cells in the peripheral blood was 53% of the total cells
(with a standard deviation of 29% and a range of 19%–80%,
n=12). We more closely examined the bone marrow in these mice
for the presence of human cell engraftment, particularly human
HSC engraftment. We found a significant population of human
CD34+ HSCs in the bone marrow (Figure 1C). The majority of
these cells coexpressed the CD45 molecule, which is indicative of
cells with lymphopoietic potential [17]. In addition, there were
significant populations of both CD3 expressing T cells and CD19
expressing B cells in the bone marrow of these mice. This
indicated that multilineage human hematopoiesis occurs in these
mice and provides evidence that, in addition to T cells, other
components of the human immune system are present. These data
demonstrated that our modification of the NSG-BLT humanized
mouse utilizing genetically modified human hematopoietic stem
cells does not negatively affect human hematopoiesis.
We then examined the animals for the presence of cells
expressing the transgenic, HIV specific TCR by MHC tetramer
staining. We found CD3+ T cells expressing the transgenic TCR
in all organs assessed, including the bone marrow, thymus, spleen,
liver, and peripheral blood of the mice receiving transduced
human hematopoietic stem cells (Figure 1D). Thus, we have
Author Summary
There is a desperate need for the development of new
therapeutic strategies to eradicate HIV infection. HIV
actively subverts the potent natural immune responses
against it, particularly cellular cytotoxic T lymphocyte (CTL)
responses. The development of a therapy that allows long-
lived immune self-containment of HIV and restoration of
these CTL responses by the host would be ideal. Through
genetic manipulation of human blood-forming stem cells,
we introduced a molecule– an HIV-targeting T cell receptor
(TCR)–that allowed the generation of functional HIV-
specific CTLs following differentiation within human
tissues in a humanized mouse model. To assess if these
newly developed, HIV-specific CTLs can allow active
suppression of HIV replication, we infected these mice
with HIV. We found that the development of genetically
modified, HIV-specific CTLs in these mice results in the
presence of a functional antiviral CTL response in vivo that
significantly lowers viral replication following HIV infection.
These results have strong implications for the use of this
technology to engineer the human immune response to
combat viral infections and suggest that genetic engi-
neering via HSCs may allow tailoring of the immune
response to target and eradicate HIV.
Engineering Antiviral Immunity from Stem Cells
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and the development of mature T cells that express the transgenic,
HIV-specific TCR in multiple organs in the NSG-CTL mouse.
Suppression of HIV replication and CD4 cell depletion in
vivo
To assess if peripheral cells resultant from human hematopoietic
stem cells that expressed the recombinant SL9-specific TCR were
capable of suppressing HIV replication in vivo, NSG-CTL mice
containing the HIV specific TCR or a control TCR were infected
with HIV-1NL-HSA-HA. HIV-1NL-HSA-HA is an engineered variant
of HIV-1NL4-3 that contains the murine heat stable antigen (HSA)
reporter gene modified to contain an Influenza hemagglutinin
(HA) antibody epitope, which is cloned into the open reading
frame of the vpr gene to allow detection of HIV-infected cells by
cell surface detection of HA expression using flow cytometry [18].
Peripheral blood was assessed for the level of productively infected
cells two and six weeks post infection. Within 2 weeks post
infection, we observed a reduced level of productively infected cells
in mice containing the HIV-specific TCR versus mice containing
the control TCR (Figure 2A). In addition, there was less initial
CD4 depletion in mice containing the HIV-specific TCR versus
mice containing the control TCR. Within six weeks post infection,
while there was an overall increase in virus-expressing cells from
the earlier time point, we observed a marked reduction in
productively infected cells in mice containing the HIV specific
TCR versus the control TCR, indicating suppression of viral
replication over time (Figure 2B). At this time point, mice
containing cells expressing the HIV-specific TCR had a greater
preservation of CD4+ T cells and higher CD4 to CD8 T cell ratios
when compared to mice expressing the control TCR. Amongst all
mice in the experiment, there was no statistically significant
difference 2 weeks following infection with either CD4 cell count
or with the percentage of cells expressing HIV, however there was
a trend towards better preservation in CD4+ cell numbers as well
as lower levels of virus-expressing cells in mice containing the
HIV-specific TCR (Figure 3). However, by 6 weeks post-infection,
there was a statistically significant difference in CD4 cell numbers
and levels of infected cells between mice with cells expressing the
HIV-specific TCR and mice with cells expressing the control
TCR. Thus, genetic modification of HSCs with a single HIV-
specific TCR produces peripheral T cells capable of suppressing
cellular HIV expression and CD4 depletion in vivo.
HIV-specific TCR suppression of plasma viremia in vivo
We next sought to determine if cells modified with an HIV-
specific TCR could suppress virus levels in peripheral blood
plasma. However, quantitating plasma viremia in the mouse
model is difficult due to the amount of plasma obtained per blood
draw (typically ,50 microliters), the limit of detection obtainable
with this amount of blood, and the high cost associated with
commercial assays. Therefore to measure viremia in this system,
we developed a novel quantitative PCR-based technique for HIV
in mouse plasma. Based on the recently elucidated secondary
structure of the HIV genome [19], primers were designed to
specifically target relatively ‘‘open’’ regions of the RNA genome
that contain minimal secondary structure to attempt to allow
increased sensitivity to detect viral RNA. Utilizing this technique,
which has a reliable sensitivity of 5 copies of HIV RNA per
sample, we determined that the viral load 2 weeks and 6 weeks
post infection was significantly lowered in mice receiving the HIV-
specific TCR versus mice receiving cells transduced with the
control TCR (Figure 4A). This suggested systemic suppression of
HIV replication in vivo. Surprisingly, analysis of the viral RNA for
mutations in the SL9 epitope did not reveal the presence of any
mutations in this epitope in the majority quasispecies, which was
identical in comparison to the sequence of the input virus and the
virus of infected mice containing the non-specific TCR control
(Figure 4B). This suggested that in this period of time, viral escape
to the selective pressure of the SL9 specific TCR had not occurred
in the blood of these mice, possibly due to limited viral replication
in this model. Thus, there was significant suppression of viral
replication in vivo in mice expressing the HIV-specific TCR versus
the control TCR and this suppression did not result in significant
viral escape within 6 weeks following infection.
TCR-engineered suppression of HIV in multiple lymphoid
organs
As illustrated in Figure 1, T cells expressing transgenic HIV-
specific TCRs were found in multiple organs in mice receiving
genetically modified HSCs. Based on this, we next addressed
suppression of HIV in multiple organs in the lymphoid
compartment in mice containing cells expressing the HIV-specific
TCR. NSG-CTL mice that had received HSCs transduced with
the HIV SL9-specific TCR or, separately, the non-specific control
TCR were infected with HIV-1NL-HSA-HA. Sets of infected animals
were then assessed 2 weeks and 6 weeks post infection for the
quantity of HIV proviral DNA sequences in human cells in the
spleen, bone marrow, and human thymus implant (Figure 5). We
observed significant suppression of HIV replication in human cells
in these organs as early as 2 weeks post infection (in the bone
marrow) in mice receiving HSC containing the HIV-specific
TCR. 6 weeks post-infection, HIV levels were significantly lower
in the spleen, bone marrow, and human thymus implant in
animals receiving the HIV-specific TCR as compared to mice
Figure 1. Construction and multilineage reconstitution of NSG-CTL mice. A. Schematic illustrating the construction of NSG-CTL mice:
CD34+ cells are isolated from fetal liver by cell sorting (1). then are transduced with lentiviral vector containing the SL9-specific TCR (2). A fraction of
these cells are then implanted under the kidney capsule in NSG mice flowing combination with fetal liver stromal elements and fetal thymus in
matrigel (3a). Another fraction of these transduced cells are viably frozen in liquid nitrogen (LN2) (3b). Three weeks following implantation, the
engrafted mice are then sublethally irradiated (3 Gy) and previously frozen cells are thawed and injected intravenously into these mice, where the
cells home to and engraft in the bone marrow (4). 6–12 weeks following injection of cells, TCR expression was analyzed and mice were infected with
HIV (5). Mouse blood is then assessed for HIV infection 2 and 6 weeks following infection (6). B. Multilineage hematopoietic reconstitution of NSG
mice receiving genetically modified HSCs. Peripheral blood from these mice were assessed by flow cytometry and gated for CD45+ human leukocytes
(top panel). These cells were assessed for the denoted cell surface marker expression including HLA-DR+CD11c+myeloid cells, CD3-CD56+ NK cells,
CD3+ T cell, CD19+ B cells. CD3+ cells were gated (lower left panel) and assessed for CD4 and CD8 expression (lower right panel). The numbers
indicate the percentage of each population of cells in the mouse peripheral blood. C. Repopulation of HSCs in mouse bone marrow. Mouse bone
marrow was assessed for the presence of CD34+ human HSCs (left panel) and CD3+ T cell and CD19+ B cell engraftment 6 weeks following CD34+ cell
injection by flow cytometry. D. Reconstitution of NSG-CTL mice with cells expressing the HIV-specific TCR transgene. Cells were isolated from the
indicated organ in NSG-CTL mice 6 weeks following CD34+ cell injection and analyzed by flow cytometry for CD3+ T cells binding SL9-containing
tetramers. The numbers indicate the percentage of T cells within the indicated organ expressing the transgenic TCR. The data are representative of
mice receiving human tissue and HIV-specific TCR transduced CD34+ cells in the same experiment identified above (n=12).
doi:10.1371/journal.ppat.1002649.g001
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PLoS Pathogens | www.plospathogens.org 4 April 2012 | Volume 8 | Issue 4 | e1002649Figure 2. Suppression of viral replication in cells in the peripheral blood. Mice receiving the HIV Gag SL-9 specific TCR (left and right panels)
or the non-specific control TCR (middle panels) were either left uninfected (left panels) or were infected with HIV-1NL-HSA-HA (right and middle panels)
and assessed for HIV (HSA-HA) expressing, human CD45+ cells (top panels) and CD4 and CD8 expression by gated CD3+ T cells (bottom panels). Mice
were assessed by flow cytometry for these cell surface markers A. 2 weeks, and B. 6 weeks post infection. The numbers indicate the percentages of
Engineering Antiviral Immunity from Stem Cells
PLoS Pathogens | www.plospathogens.org 5 April 2012 | Volume 8 | Issue 4 | e1002649receiving the control TCR. In addition, analysis for proviral DNA
in human cells in the pooled peripheral blood cells (n=3 mice per
treatment group), revealed a similar trend, with 37 copies and 529
copies of HIV per 10,000 human cells at 2 weeks and 6 weeks post
infection respectively, in mice containing the HIV-specific TCR,
and 356 copies and 792 copies of HIV per 10,000 human cells at 2
weeks and 6 weeks, respectively, in mice containing the control
TCR. Thus, these data indicate that there is significant
suppression of HIV in multiple lymphoid tissues in animals
receiving HSCs genetically modified to produce cells that
specifically target HIV infected cells.
Effector function of TCR-engineered CD8+ T cells and
viral control in vivo
We assessed the antiviral effector function of CTLs expressing
HIV-specific transgenic TCRs in mice receiving genetically
modified HSCs. In an additional series of experiments, mice
containing the SL-9 specific TCR were infected with HIV or left
cells that exist with each of the respective quadrants. The data are representative of the phenotypic profile of 1 mouse of 6 mice receiving the SL-9
specific TCR, and 1 mouse of 6 receiving the control TCR and are representative of 3 separate experiments with a minimum of 3 mice in each
experimental group.
doi:10.1371/journal.ppat.1002649.g002
Figure 3. Suppression of HIV replication by HIV-TCR containing T cells. A. Suppression of HIV-1 induced CD4 cell depletion by cells
containing HIV-specific TCR. Mice containing cells derived from HSC transduced with either HIV Gag SL9-epitope specific TCR (n=6 mice) or a non-
specific control TCR (n=7 mice) were infected with HIV-1HSA-HA or left uninfected (n=4 mice)(SL9-specific TCR containing mice) and assessed 2 weeks
and 6 weeks following infection for peripheral human CD45+, CD4+ cells. Statistical comparison of CD4 cell depletion to uninfected controls was
performed using the Student’s t test, p values are provided for each indicated comparison. The solid lines represent the mean +/2 the standard error
of the mean (SEM). B. Suppression of HIV expressing cells. Mice treated as described in (A) were assessed for human CD45+ cells expressing HIV by
flow cytometry for the HSA-HA marker gene. Comparison of HIV expression levels between SL-9 containing and control TCR-containing mice are
provided at week 2 and week 6 post infection (Student’s t test). The data represent 1 experiment of 3, with a minimum of 3 mice per experimental
condition, and is a separate experiment than that depicted in Figure 2.
doi:10.1371/journal.ppat.1002649.g003
Engineering Antiviral Immunity from Stem Cells
PLoS Pathogens | www.plospathogens.org 6 April 2012 | Volume 8 | Issue 4 | e1002649uninfected and cells from the peripheral blood were assessed for
phenotypic changes that would suggest differentiation. HIV
infection resulted in phenotypic differentiation of HIV specific
cells, as determined by SL9 MHC tetramer staining, into cells
possessing an effector phenotype [20,21](CD8+SL9Tetramer+C-
D45RA-CCR7-)(Figure 6A). This was similar to the phenotypic
changes we observed in previous studies following ex vivo peptide
stimulation of SL9-specific, TCR transgenic thymocytes [11] and
in vivo responses to the MART-1 tumor antigen by MART-
specific CD8 cells [22]. This increased loss of CD45RA and
CCR7 expression that we observed in HIV- specific TCR-
expressing cells in infected mice versus uninfected mice is
indicative of antigen-specific induction of cellular differentiation.
We then more closely analyzed the differences we observed viral
suppression by and expansion of HIV-specific CTLs in vivo in
infected mice. We found a significant correlation between the
highest levels of reconstitution of HIV-specific TCR-expressing
cells prior to infection and more effective suppression of viral loads
in the serum six weeks following infection (Figure 6B). Interest-
ingly, we noted that at six weeks following infection, mice that had
greater levels of HIV-specific TCR-expressing cells in the
peripheral blood had higher viral loads at this time point
(Figure 6C). In addition, we saw significant antigen-driven
expansion of HIV-specific TCR-expressing CTLs in infected
animals compared to controls, with the greatest levels of expansion
seen in animals with the lowest initial (week -2) transgenic TCR
reconstitution (Figure 6D). Taken together, these results suggest
that greater initial reconstitution of transgenic HIV-specific cells is
more effective at controlling early viral replication. Furthermore
these data suggest that the higher resultant viral loads in animals
with initially low human immune reconstitution drive greater
antigen-specific cell expansion over time. Thus, CTLs expressing
the HIV-specific TCR undergo antigen-driven phenotypic
differentiation and expansion in this model, which correlates with
control of viral replication.
Figure 4. Suppression of HIV and viral evolution in the plasma
of NSG-CTL mice. A. Blood plasma from the same HIV-1HSA-HA
infected mice as described in Figure 3 was collected 2 weeks and 6
weeks post infection. Viral RNA (vRNA) levels per sample (typically 50 ml
of plasma per mouse) were determined by quatitative reverse
transcriptase (RT)-PCR and results were multiplied by a standard factor
to yield copies of vRNA per milliliter (ml) of blood. The points represent
the copies of HIV vRNA per milliliter (ml) of blood and the solid line
represents mean per group (+/2 SEM). Statistical comparison was
performed between SL9-specific TCR containing mice and non-specific
TCR-containing mice and p values are provided (Student’s t test). The
dotted line indicates the limit of detection of the assay. The data are
representative of 3 separate experiments, with a minimum of 3 mice
per experimental condition, and utilized the same mice depicted in the
experiment described in Figure 3. B. Evolution of the SL9 epitope in
infected mice. Viral stock of the input virus, and virus from plasma of
mice containing the control TCR or virus from plasma of mice
containing the SL9-specific TCR 6 weeks following infection was
sequenced utilizing a RT-PCR technique. The translated sequence is
provided for each sample, with the SL9 epitope highlighted in bold.
doi:10.1371/journal.ppat.1002649.g004
Figure 5. Suppression of HIV in multiple lymphoid compart-
ments in NSG-CTL mice. HIV proviral DNA was quantitatively
assessed in human cells from mouse spleen (top panel), bone marrow
(middle panel), and human thymus implant (bottom) (n=3 mice per
group) 2 weeks (left side) and 6 weeks (right side) post infection. The
points represent the copies of HIV proviral DNA per 10,000 human cells
and the solid line represents mean per group (+/2 SEM). Statistical
comparison and p values were calculated using the WRST. The data
represent 1 experiment of 2 separate experiments where these multiple
organs were analyzed with a minimum of 3 mice per experimental
condition and is derived from the same experiment depicted in
Figures 3 and 4.
doi:10.1371/journal.ppat.1002649.g005
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The CTL response has a pivotal role in controlling HIV
replication in infected individuals. While HIV generates a potent
natural immune response during the acute stage of infection, this
response does not result in the control of viral replication or
clearance of the virus from the body [4–6]. There are critical
defects in the CTL response that result during chronic viral
infection. These defects include the inadequate generation of a
functional response due to low antigen-specific precursor frequen-
cy, expression of functional inhibitory molecules such as
programmed death-1 (PD-1) and T-cell immunoglobulin domain
and mucin domain 3 (TIM-3), and Cytotoxic T-Lymphocyte
Antigen 4 (CTLA-4), and activation of suppressor cell activity [23–
26]. In addition, HIV can directly or indirectly perturb viral
antigen presentation, immunoregulatory cytokine production, T
Figure 6. Effector cell differentiation and control of viral replication. A. Peripheral blood from uninfected (left column) and HIV infected
(right column) mice was analyzed six weeks post infection with HIV for expression of CD8, the transgenic HIV-specific TCR (SL-9 Tetramer), and the
CD45RA and CCR7 differentiation markers. The top row displays gated CD8+ T cells expressing the transgenic HIV-specific TCR. CD8+ cells expressing
the transgenic TCR are indicated in the box gate and the percentage of total CD8+ cells expressing the transgenic TCR is provided in the gate. The
bottom row displays the CD45RA versus CCR7 staining profile of the CD8+, SL-9 tetramer+cells in the gates indicated in the top row with the
percentage of cells in each quadrant provided in their respective quadrants. B. Levels of transgenic HIV-specific TCR+, CD8+ T cells reconstituting
mice 2 weeks prior to HIV infection versus viral load 6 weeks following HIV infection. The levels of SL-9 tetramer+cells of the CD8+ T cell population in
individual mice were assessed in peripheral blood 2 weeks (week -2) prior to HIV infection by flow cytometry and are provided on the y-axis. The x-
axis indicates the serum viral loads of these individual mice 6 weeks following infection. The data significantly correlate as determined by the SRCT
and the p value is provided. Note that initially high levels of immune reconstitution correlate with lower viral loads at the 6 week time point. The
dotted line indicates the limit of detection of the assay. C. Levels of transgenic HIV-specific TCR+, CD8+ T cells versus viral load 6 weeks following HIV
infection. Data were analyzed as described above 6 weeks post HIV infection. The data significantly correlate as determined by the SRCT and the p
value is provided. Note that at this time point, higher levels of CTL in the blood are found in animals with higher viral load. The dotted line indicates
the limit of detection of the assay. D. Antigen-driven expansion of CD8+, HIV-specific TCR expressing cells in HIV infected mice. Levels of SL9 tetramer
staining, CD8+ T cells were assessed in the peripheral blood of infected animals (solid lines) or uninfected animals (dashed lines) two weeks prior to
infection (week -2), and 4 and 6 weeks post infection. Data is expressed as the percentages of tetramer+cells of total CD8+ T cells. Note that the level
of HIV-specific cells in animals showing initially low levels of reconstitution are considerably higher at the late time point, suggesting proliferative
response to the high levels of antigen. The data are representative of 1 of 3 separate experiments with a minimum of 3 mice per experimental
condition.
doi:10.1371/journal.ppat.1002649.g006
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infect CTLs themselves [27–33]. The maintenance of a potent
antiviral CTL response is critical in all stages of infection and there
are strong associations between the preservation of CTL responses
specific for more conserved HIV epitopes, greater control of viral
replication, and slower disease progression [5,6].
In the present study, we demonstrate the feasibility of
engineering human hematopoietic stem cells to become peripheral
T cells capable of targeting HIV replication in vivo. Our previous
studies provided evidence that the genetic modification of human
hematopoietic stem cells with a lentiviral vector containing an
antigen-specific TCR (specific to the SL9 Gag epitope) allowed the
development of functional human T cells in human thymus
implants in SCID-hu mice [11]. While this study demonstrated
that transgenic TCR-containing T cells are capable of developing
in the human thymus, the ability of these cells to target and kill
HIV infected cells in vivo was not known. In the present study, we
use an improved chimeric mouse model exhibiting a high degree
of human immune cell reconstitution to significantly extend these
observations to demonstrate that mature T cells expressing an
antigen-specific human TCR are capable of developing and
migrating to peripheral organs in vivo. In contrast to the SCID-hu
Thy/Liv model, which is an excellent model for studies examining
human thymopoiesis but limited in examining peripheral immune
responses [34], we utilized a variation of the humanized BLT
mouse model utilizing the NSG strain that allows multilineage
hematopoiesis and human cell repopulation in peripheral organs
[35,36]. The generation of natural immune responses to HIV in
these systems appears to be relatively limited, particularly the
ability of these mice to elicit HIV specific human T cell responses
which is likely due to incomplete human immune cell reconsti-
tution, particularly antigen presenting cell reconstitution, to the
levels seen in humans [12,36,37]. In addition, lower antigen-
specific cell precursor frequency and the lack of or lower levels of
human-specific cellular support immune components (such as
costimulatory or immunoregulatory molecules, adhesion mole-
cules, and cytokines) likely contribute to the lower levels of
antiviral immune responses generated in humanized mice. The
incomplete and varied immune reconstitution in the current
humanized mouse systems results in differences in immune
responses and kinetics of viral pathogenesis compared to natural
HIV infection in humans. The reasons for this are unclear and
vary between the different types of humanized mouse models;
however, there are many similarities and parallels between HIV
infection in humanized mice and humans which makes these
surrogate models very powerful in their ability to allow the close
examination of many aspects of HIV infection, transmission,
pathogenesis, immunity, and therapeutic intervention [36]. While
natural antiviral T cell immune responses are limited in current
humanized mouse models, our studies suggest that the genetic
‘‘programming’’ of HSCs to produce T cells specific for HIV can
overcome this limitation in this system and produce measurable T
cell responses that have a significant antiviral effect in vivo. Further,
we found it startling that the use of a single HIV-specific TCR can
result in significant HIV suppression while natural suppressive
antiviral CTL responses are polyclonal. These observations can
provide the platform for future studies that allow the closer
examination of the generation of human antiviral immune
responses and the identification of factors involved in the
persistence and potential eradication of HIV infection.
Previous attempts utilizing a gene therapy approach towards
enhancing antigen specific cellular immune responses have
focused on ‘‘redirecting’’ mature T cells towards viral or cellular
antigens [38–46]. In these cases, genes for HIV-specific T cell
receptors (TCRs) or chimeric antigen specific receptors were
utilized to modify mature T cells to specifically target virus infected
cells or malignancies. In some cases of the latter, tumor regression
has occurred in treated individuals [45–47], which suggests that
the genetic modification of T cells towards a specific antigen is
feasible in vivo in humans and alludes to the potential for the
further development of these strategies to target other diseases.
However, the modification of mature T cells has several
limitations, including the possibility of endogenous TCR miss-
pairing with the newly introduced TCR, the development of
intrinsic functional defects and/or the alteration of cellular
effector/memory maturation pathways in the cells following heavy
ex-vivo manipulation [47], and the maintenance of long-lived fully
functional cells. A stem cell-based approach where HSCs are
modified with an antigen specific receptor, however, may abrogate
these complications by allowing the long term, continual natural
development of mature T cells that bear the transgenic antigen-
specific molecule. Normal development of these cells in the bone
marrow and selection in the thymus would reduce the possibility of
producing cells that are autoreactive through TCR miss-pairing
and functionally altered through ex vivo manipulation, major
drawbacks of mature T cell modification. We have recently shown
that genetic modification of human HSC with a TCR specific for
human melanoma allows the generation of melanoma-specific
human T cells capable of clearing tumors in BLT mice [48]. Our
current studies extend this type of approach to demonstrate the in
vivo efficacy of TCR-modified stem cells to generate antigen-
specific T cells that target a rapidly replicating viral infection in
vivo. Our results document the ability of the resulting HIV-specific
CTLs to dramatically reduce viral replication and consequent
CD4 cell loss in a relevant model of HIV pathogenesis.
Recent stem cell-based attempts at protecting cells from direct
infection by HIV through the modification of HSCs with antiviral
genes or genes that knock down viral coreceptors [16,49,50]
require high percentages of HSCs to be genetically modified to be
protected from infection. Our results suggest that the approach of
genetically vaccinating cells to target HIV infection would require
much lower levels of genetic modification. Modification of human
HSCs with a transduced TCR results in significantly increased
naı ¨ve, antigen specific precursors. This level of transduction is
sufficient to result in decreased viral replication and increased
immune protection. Correspondingly in humans, uninfected
HLA-A*0201+ individuals have an estimated natural SL9
epitope-specific, naı ¨ve CTL precursor frequency of approximately
one in 3.3610
6 cells in the peripheral blood, which is similar to the
precursor frequency of naı ¨ve cells specific to a variety of other viral
antigens [51]. In our studies, the TCR-transduced population
typically accounted for 0.75–5.5% of the CD8+ T cell population
in a given organ in the mouse following their differentiation from
HSCs (the illustration in Figure 1D represents a single mouse from
a single experiment). The frequency of transgenic cell reconstitu-
tion did not correlate with transduction efficiencies of the vector
into the stem cells, rather it appears to be due to individual
engraftment rates of CD34+ cells into each mouse. However, even
at low frequencies of transgenic TCR expressing cells, this
represents a significant increase in the naı ¨ve cell precursor
frequency for cells specific to the SL9 Gag epitope, as mice
harboring the control non-specific TCR and untransduced mice
had undetectable levels or very low levels of natural SL9-specific
CTLs as determined by MHC tetramer staining. Utilizing TCR
gene transductions to yield increases of HIV-specific precursor
frequency to conserved antigenic epitopes could potentially
reconstitute innate defects in the ability of peripheral T cells to
clear infected cells. While the human thymus involutes over time,
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retain some activity throughout life [52,53]. A recent study
involving introduction of an antiviral gene into the autologous
HSC of HIV infected adults illustrated that naı ¨ve T cells bearing
the transgene were detected in the peripheral blood of these
subjects, indicating that genetically engineered T cells can develop
from HSC in adult HIV infected subjects [54]. Through this type
of therapeutic intervention, our results suggest the feasibility of
supplying newly developed, naı ¨ve antigen-reactive cells, that could
allow the overall T cell response to overcome limits in the
magnitude of the response that inhibit effective viral clearance.
This type of gene therapy-based approach could further
diversify the breadth of the responses by naı ¨ve, antigen specific
cells by utilizing TCRs specific to other epitopes of HIV. The use
TCR gene transduction as a therapeutic approach would have to
be tailored to the HLA type of the individual receiving treatment
in order to produce cells that survive T cell selection processes.
Immune epitope escape from the transduced TCR, which did not
occur in the time frame of our experiments, is likely to occur in vivo
in a clinical setting. One potential caveat of the humanized mouse
model is the lower level of human immune cell reconstitution than
is seen in humans; which significantly, yet incompletely,
recapitulated the human immune system in the mouse. While
HIV replication rates and viral loads persist detectably over weeks,
they do not achieve the levels observed in natural infection in
humans. This lower level of viral replication is one potential reason
that viral escape mutants to the SL9-specific TCR may be slower
to develop. The potential for viral immune escape necessitates the
use of multiple TCRs in a therapeutic setting targeted to the
antigen or antigens of interest. Careful selection of multiple TCRs
targeted to relatively conserved antigenic epitopes within defined
HLA types could reduce the possibility of viral epitope evolution
and immune escape, perhaps driving the evolution of the virus into
a less fit state [55]. The evidence that immune escape and viral
evolution against many specific epitopes occurs relatively slowly
suggests that an engineered immune response and the immune
pressure created by these antigen-specific cells may be therapeu-
tically beneficial by lowing viral replication, decreasing levels of
infected cells, and impairing the fitness state of the virus [55,56]. In
sum, our results demonstrate the feasibility of a therapeutic
approach that involves the modification of human HSCs by
delivering genes for antigen-specific TCR to produce peripheral,
naı ¨ve, antigen-specific T cells that are capable of reducing HIV
replication in vivo. These studies provide a foundation and a model
system that would allow the closer examination of human antiviral
T cell responses and the development of therapeutic strategies that
target chronic viral infection.
Materials and Methods
Ethics statement
Peripheral blood mononulear cells was obtained at the
University of California, Los Angeles in accordance with UCLA
Institutional Review Board (IRB) approved protocols under
written informed consent using an IRB-approved written consent
form by the UCLA Center for AIDS Research Virology
Laboratory and Dr. Yang and was distributed for this study
without personal identifying information. Human fetal tissue was
purchased from Advanced Biosciences Resources or from
StemExpress and was obtained without identifying information
and did not require IRB approval for its use. Animal research
described in this manuscript was performed under the written
approval of the UCLA Animal Research Committee (ARC) in
accordance to all federal, state, and local guidelines. Specifically,
these studies were carried out under strict accordance to the
guidelines in The Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health and the accreditation
and guidelines of the Association for the Assessment and
Accreditation of Laboratory Animal Care (AALAC) International
under UCLA ARC Protocol Number 2010-038-02B. All surgeries
were performed under ketamine/xylazine and isofluorane anes-
thesia and all efforts were made to minimize animal pain and
discomfort.
Antibodies, tetramers, and flow cytometry
The following antibodies were used in flow cytometry: CD3,
CD4, CD11c, CD8, CD45, CD45RA, CD34, HLA-DR (Coulter),
CD19, CD56, CCR7, HSA, and IgG controls (eBioscience),
hemagglutinin (HA) sequence YPYDVPDYA (Roche), and HLA-
A*02 (Serotech). HLA-A*0201 tetramer containing the HIV Gag
SL9 SLYNTVATL (SL9) peptide was purchased from Coulter.
Cell surface marker expression was analyzed utilizing antibodies
conjugated to either fluorescein isothiocyanate (FITC), Peridinin
Chlorophyll Protein (PerCP)-Cy5.5, phycoerythrin (PE), electron
coupled dye (ECD), PE-Cy5, PE-Cy7, allophycocyanin (APC),
APC-Alexa750, APC-eFluor780, Alexa700, eFluor405, Pacific
Blue, or Pacific Orange in appropriate combinations. Cells were
acquired on a LSR II flow cytometer (BD Biosciences) using
FACSDiva software. FlowJo software was used for analysis.
Lentiviral vector production
Lentiviral production from the plasmid containing the HIV SL9
specific TCR (pCCL.PPT.hPGK.1.9.IRES.eGFP) or a control
TCR with an unknown specificity (pCCL.PPT.hPGK.a4.IRE-
S.eGFP) was produced using the Invitrogen ViraPower Lentiviral
Expression System using the pCMV.DR8.2.Dvpr packaging
plasmid and the pCMV-VSV-G envelope protein plasmid as
previously described [11].
Construction of NSG-CTL mice
NSG mice were initially purchased from Jackson Laboratories
and bred at the UCLA Division of Laboratory Animal Medicine.
To construct NSG-CTL mice, fresh human HLA-A*0201+ fetal
liver and thymus pairs from the same donor were obtained from
Advanced Biosciences Resources or from StemExpress. Fetal liver
was then homogenized and CD34+ cells were isolated as described
[11]. Briefly, fetal liver is diced into small (,3 mm) pieces,
homogenized and digested with collagenase type IV (1 mg/ml),
hyaluronidase (1 mg/ml), DNase I (2 U/ml)(Sigma). CD34+ cell
were purified using magnetic activated cell sorting (Miltenyi). The
negative fraction of cells, which contains fetal liver stromal cells
(CD342 cells) is saved. CD34+ cells were then genetically
transduced following resuspension in Yssel’s medium containing
2% human serum albumin and placed in a tissue culture plate
coated with 20 mg/ml retronectin (Takara Bio, Inc.) along with
lentiviral vector at a multiplicity of infection of 5 overnight at 37u.
Fetal liver stromal cells and the matched fetal thymus, cut into
small pieces (2 mm), were cultured at 37u overnight in RPMI-1640
containing 10% fetal calf serum (FCS) and 0.44 mg/ml Piptazo.
The next day, tissue and cells were washed with PBS and a
fraction of the transduced CD34+ cells were then viably frozen.
The remaining CD34+ cells were combined with fetal liver
stromal cells in cold Matrigel (BD Biosciences) in a 1:9 ratio
(CD34+ cells:fetal liver stromal cells, typically 500,000 transduced
CD34+ cells:4,500,00 fetal liver stromal cells) and combined with a
2 mm fetal thymus piece in a trocar and placed under the kidney
capsule of NSG mice. Transduction efficiency was determined
following culturing in IMDM containing 20%FCS, 50 ng/ml of
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fluorescence by flow cytometry. Transduction efficiency of CD34+
cells occurred at a mean rate of 12.7% (Standard devia-
tion=12.6%, range 1.63%–38.5%, n=14). Three weeks following
implantation, mice were irradiated with 3 Gy using a cobalt-60
source to clear a niche for human CD34+ cell engraftment of the
bone marrow. The frozen CD34+ cells were then thawed and then
injected intraveneously into the mice. Mice were then checked for
human cell engraftment 6–10 weeks post-injection. Multiple
experiments were performed with a minimum of 3 mice per
experimental group to yield statistical significance. Each experi-
ment utilized humanized mice that were made from human tissue
from same donor and the donor tissue was unique experiment to
experiment.
HIV growth and infection
A virus variant of HIV-1NL4-3-HSA-HA containing the mouse
heat stable antigen (HSA) which has been modified to contain the
influenza virus hemaggluttin YPYDVPDYA sequence (HA) cloned
into the vpr open reading frame, and which also contains the SL9
Gag epitope, has been previously described [18]. Virus was grown
in CEMx174 from plasmid-derived virus stock. Viral infectivity
was determined by limiting dilution titration on CEMx174 cells.
Mice were infected by intraperitoneal injection 10–12 weeks
following CD34+ cell injection with 50–100 ng of previously
frozen virus stock.
Reverse-transcriptase, real time PCR for viral RNA in
mouse plasma
Mouse blood peripheral blood was drawn by retro-orbital
bleeding into glass capillary tubes coated with 330 mM EDTA
(Gibco), and 3% sterile human serum albumin (Baxter Health-
care). Viral RNA was extracted from plasma with the High Pure
Viral RNA Kit (Roche). The kit is designed to extract 200 mlo f
plasma. Since there is generally less plasma than this, the volume
was estimated by weight and brought up to 200 ml with phosphate
buffered saline (Gibco). DNA standards and the template for in
vitro transcribed RNA for quantitative PCR was derived from
pNL101 linearized with EcoRI, checked with electrophoresis, and
quantitated by spectrophotometry (A260). A section of the gag gene
in pNL101 was amplified with the primers NG1CF, position 366–
398 (59-GGAGAATTAGATAAATGGGAAAAAATTCGGT-
TA-39) and NG1CR position 679–648 (59-GCCTTTTTCT-
TACTTTTGTTTTGCTCTTCCTC-39), and cloned into
pCR4TOPO. The product containing the cloned gag was then
digested with SpeI and BsrGI and gel purified. This fragment was
then translated to RNA with T7 RNA polymerase (Promega
Riboprobe Transcription Kit) and quantitated by spectrophotom-
etry (A260). This RNA was serially diluted in The RNA Storage
Buffer (Ambion) with 0.4 U/ml Rnasin and 5 ng/ml Lambda
DNA/HindIII (as carrier), to make a stock of 500,000 copies/ml.
Before each RT run, a fresh vial of RNA was serially diluted in the
RNA Storage Buffer (Ambion) to make standards of 100,000 to 10
copies. Quantitative reverse transcriptase-PCR (RT-PCR) was
performed using the following primers/probe specific for gag
sequences: NG1F (position 453–480) 28 bp (59-GAGCTAGAAC-
GATTCGCAGTTAATCCTG-39), NG1R (position 570–534)
37 bp (59-ATAATGATCTAAGTTCTTCTGATCCTGTCTG-
AAGGGA-3), NG1Z probe (position 482–520) 39 bp (FAM-59 -
CCTTTTAGAGACATCAGAAGGCTGTAGACAAATACTG-
GG-3-BHQ).
The final reaction concentration consists of 2.5 mM NG1F,
7.5 mM NG1R, and 2.5 mM NG1Z. These primers were based on
sequences identified to be in relatively ‘‘open’’ regions of HIV
RNA not impeded by secondary structure interference as
determined by [19].
Reverse transcription was performed using the SuperScript III
kit (Invitrogen). The annealing step consisted of 5 ml of template
RNA plus 3 ml of a mixture consisting of 1.5 parts 20 mM NG1R,
0.5 parts Rnasin plus (Promega), 16 parts 56RT buffer, and 12
parts water. The resulting 8 ml was heated to 70u for 2 minutes,
then at 60u for 5 minutes, then cooled to room temperature. The
RT step was run by adding 2 ml of a mixture of 8 parts water, 4
parts 56buffer, 5 parts DTT, 2 parts 25 mM dNTPs (Invitrogen),
and 1 part SuperScript III. This was heated to 55u for 30 minutes,
85u for 5 minutes, then cooled to room temperature.
For quantitative DNA PCR following the reverse transcription
step, 15 ml of the PCR mix consisting of 38.5 parts water, 44 parts
25 mM MgCl2, 50 parts NG-FRZ oligos, 5 parts 500 mM Tris
buffer pH 8.3, 8.5 parts 1 M KCl, 2.5 parts 25 mM dNTPs, and
1.25 parts Platinum Taq was added to all wells that underwent the
reverse transcription reaction and mixed. Real-time, quantitative
PCR was performed with 5 minutes activation at 95u, and
followed by 45 cycles of 95u for 15 seconds and 60u for one
minute on a BioRad CFX96 thermocycler. An additional set of
DNA standards, serially diluted from 2610
5 copies to 20 copies, of
linearized pNL101 was run in parallel to control for the efficiency
of the RT step. Results from samples were interpolated within the
quantitation derived from the RNA standards.
Statistical analysis
Statistical support was provided through the UCLA Center for
AIDS Research (CFAR) Biostatistical Core. Experiments were
analyzed utilizing the Student’s t test, the Spearman rank
correlation test (SRCT), or the Wilcoxon Rank Sum Test
(WRST)(when n=3), as indicated.
Sequencing the majority quasispecies from mouse
plasma
Evolution/mutation of the dominant version of the introduced
Gag-SL9 epitope sequences from the plasma of mice infected with
HIV-1NL4-3-HSA-HA was determined by bulk sequencing of the
segment of the Gag coding region. Plasma viral RNA was isolated
as described above and cDNA was synthesized utilizing the
Superscript cDNA synthesis kit (Applied Biosystems). Alternative-
ly, proviral DNA from lymphocytes on infected mice was isolated
as described above. Utilizing these DNAs, the region of the HIV-1
Gag flanking the SL9 epitope (a.a. 77–85) was PCR amplified
using the 737-Forward primer (59-GCGACTGGTGAG-
TACGCC-39) and the 1255-Reverse primer (59-ACCCATG-
CATTTAAAGTTC-39) and purified by Gel-purification (Qiagen
Inc., USA). This purified bulk PCR product was then directly used
for dye-terminator sequencing with both 737-Forward and 1255-
Reverese primers in parallel. The data was then analyzed by the
ABI-3130 genetic analyzer (Applied Biosystems, USA).
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